MedTrace Logo

Comparison of Intravenous Brivaracetam Versus Levetiracetam in the Management of Status Epilepticus

NCT07163572 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2025-09-09

No results posted yet for this study

Summary

Brivaracetam is increasingly being studied in adult status epilepticus populations, evidence in pediatric patients remains sparse, with only limited case series and observational studies reporting favorable outcomes. This study aims at direct comparison between intravenous brivaracetam and levetiracetam in the acute management of pediatric status epilepticus.

Conditions

  • Status Epilepticus

Interventions

DRUG

Intravenous brivaracetam

Patients received intravenous brivaracetam as a loading dose of 2 mg/kg (maximum 100 mg) diluted in 100 ml of normal saline infused over 10 minutes.

DRUG

Intravenous levetiracetam

Patients received intravenous levetiracetam as a loading dose of 40 mg/kg (maximum 3000 mg) diluted in 100 ml of normal saline infused over 10 minutes.

Sponsors & Collaborators

  • Muhammad Aamir Latif

    lead OTHER

Principal Investigators

  • Ikram Rahman · Children's Hospital and institute of Child Health, Multan, Pakistan

  • Nuzhat Noureen, FCPS · Children's Hospital and institute of Child Health, Multan, Pakistan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Month
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-16
Primary Completion
2025-08-16
Completion
2025-08-16

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07163572 on ClinicalTrials.gov